GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid
This is a problem we call the Quality-Price Gap. We put Hers under the microscope to see how it measures up on safety, cost, and long-term support, helping you bridge the gap between safety and affordability
In general, weight loss medications are recommended for people who: Have a body mass index (BMI) of 30 or higher Have a BMI of 27 or higher, plus a weight-related condition like high blood pressure or type 2 diabetes Find out how much you could lose Provide your biometric data to get started
Other perks include app-based features like real-time insurance process tracking and treatment notifications, side effect guidance and FAQs, educational materials, and more
Orforglipron is a next-generation oral GLP-1 agonist that could eventually make daily pills as effective as weekly injections
Complete prevention is not guaranteed, but you can significantly reduce your risk and severity